Open Access Articles- Top Results for Dirlotapide


Systematic (IUPAC) name
Clinical data
AHFS/ International Drug Names
481658-94-0 7pxY
PubChem CID 9917862
ChemSpider 8093509 7pxY
UNII 578H0RMP25 7pxY
KEGG D03867 7pxY
ChEMBL CHEMBL410414 7pxY
Chemical data
Formula C40H33F3N4O3
674.71 g/mol
 14pxY (what is this?)  (verify)

Dirlotapide is a drug used to treat obesity in dogs. It is manufactured by Pfizer and marketed as Slentrol.

It works as a selective microsomal triglyceride transfer protein (MTTP) inhibitor. This blocks the assembly and release of lipoproteins into the bloodstream, thereby reducing fat absorption. It also elicits a satiety signal from lipid-filled cells lining the intestine.

It is supplied as an oral solution. It is not intended for use in humans, cats, or parrots.

On January 5, 2007, the U.S. Food and Drug Administration (FDA) approved Slentrol, the first time the FDA has approved a drug for obese dogs.[1]

Dirlotapide is used to manage obesity in dogs and helps by reducing appetite. It should be used as part of an overall weight control program that also includes proper diet and exercise, under the supervision of a veterinarian. Side effects may include vomiting, diarrhea, lethargy, drooling, or uncoordination. Allergic reaction to the medication may include, facial swelling, hives, scratching, sudden onset of diarrhea, vomiting, shock, seizures, pale gums, cold limbs, or coma. Contact your veterinarian if you observe any of these signs. The dose of dirlotapide will need to be recalculated each month, based on your dog's weight.

Canine patient information sheet


  1. "FDA approves 1st drug for obese dogs". Yahoo. Archived from the original on January 8, 2007. Retrieved 2007-01-06. 

External links